HypercholesterolemiaCEPHEUSNCT00542867
Pan-European Survey on the Under Treatment of Hypercholesterolemia
An observational study of Hypercholesterolemia, run by AstraZeneca.
Trial summary
The survey try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.· Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypercholesterolemia
- How many people
- 6,500 participants
- Where
- No sites listed yet
- Study dates
- Jan 2006to Nov 2007
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
Who cannot join
None listed.
About this study
The survey try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.·
- Conditions
- Hypercholesterolemia
- Keywords
- Hypercholesterolemia, Third Joint European Task Force guidelines, Survey
- Medical subject headings
- Hypercholesterolemia
What is being measured
The primary outcome is the main question the study is designed to answer.
The number and percentage of patients achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Oct 2007 (estimated)
- Study startJan 2006
- Study completionNov 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HypercholesterolemiaStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 6,500 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- M. Hermans, Principal investigator, UCL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00542867
- Sponsor's protocol ID
- SRP-CB-CRE-2006/01
- Acronym
- CEPHEUS
- Status last verified
- Nov 2007
- First submitted
- 11 Oct 2007
- Last updated
- 20 Nov 2007
- Results posted
- No
- Data monitoring committee
- No
Publications
Hermans MP, Castro Cabezas M, Strandberg T, Ferrieres J, Feely J, Elisaf M, Michel G, Sansoy V. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010 Feb;26(2):445-54. doi: 10.1185/03007990903500565.
PubMed 20001658